Dual-Drug Containing Core-Shell Nanoparticles for Lung Cancer Therapy

Late-stage diagnosis of lung cancer occurs ~95% of the time due to late manifestation of its symptoms, necessitating rigorous treatment following diagnosis. Existing treatment methods are limited by lack of specificity, systemic toxicity, temporary remission, and radio-resistance in lung cancer cell...

Descripción completa

Detalles Bibliográficos
Autores principales: Menon, Jyothi U., Kuriakose, Aneetta, Iyer, Roshni, Hernandez, Elizabeth, Gandee, Leah, Zhang, Shanrong, Takahashi, Masaya, Zhang, Zhang, Saha, Debabrata, Nguyen, Kytai T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5643549/
https://www.ncbi.nlm.nih.gov/pubmed/29038584
http://dx.doi.org/10.1038/s41598-017-13320-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5643549/
https://www.ncbi.nlm.nih.gov/pubmed/29038584
http://dx.doi.org/10.1038/s41598-017-13320-4

Ejemplares similares